Subject Index

Academic sector, funding from, 285
Acute lymphoblastic leukemia (ALL), 206
Acute myeloid leukemia (AML), source of relapse in, 207
Adenosine deaminase (ADA), early gene therapy applications and, 3
Adenoviral vector studies, 203
Adenovirus
  receptor-mediated entry mechanism of, 40
  YO type, 101
Adenovirus cystic fibrosis transmembrane conductase regulator (AdCFTR), 93
Adenovirus-polylysine-DNA complexes, gene transfer mediated by, 36
Adverse Experiences, list of, 290
AIDS activist groups
  impact of, 18, 22
  public discussions sought by, 301
Alkalating agents
  potency of, 71
  risk of, 101
Allogeneic melanoma, CTL response and, 181
Allogeneic MHC molecules, 324
Animal studies, regulation of, 287
Antibody-dependent cell-mediated cytotoxicity (ADCC), D612 mAb and, 157
Anti-FcRγIII receptor antibody, ADCC and, 158
Antisense molecules, ribozymes vs., 254
Antisense therapeutics, development of, 228
α1-Antitrypsin (α1AT)
  human, 92
  expression of, 101
α1-Antitrypsin disease, 102
Antitumor effect
  IL-12 exhibited, 88
  IL-12 stimulated, 75
Apoptosis
  immunity induced by, 203
  p53 and, 268
  tumor suppressor gene and, 280
Arthritis, gene therapy for, 80
Articular joints, adenovirus and, 94
Asialofetuin (AF), 331
Asialoglycoprotein (AGP), 331
Autologous bone marrow transplantation (ABMT)
  relapse in, 226
  rhesus monkey and, 217
  source of relapse after, 205

B16 cell, murine melanoma, 75
B16Fl0 cells, mγ-IFN vector-transduced, 172
Backbone linkages, 234
Benefit, emphasis of, 299
Biotinylated β-galactosidase (BAG) DNA, 336
Biotinylated β-galactosidase (BAG) mobilization assay, 309
BL-6 cells, 75
Bleomycin, pulmonary fibrosis and, 258
Bleomycin hydrolase (BH), 259
Blood vessels, adenovirus and, 94
Bone marrow, mouse, expression of human *MDR*1 gene in, 128
Bovine leukemia virus (BLV), 64
Brain, adenovirus and, 94
Breast carcinoma, VDEPT against, 118

5-Bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal), 92
MFG-glucocerebrosidase and, 314

C-5 propyne pyrimidines, 236
C2Cl2 myoblasts, transduction of, with MFG-glucocerebrosidase, 310
C43 fluorochrome, 312
Cancer
cationic liposomes for direct gene transfer in therapy of, 23
clincical trials in gene therapy and, 21
endothelial cell targeting for, 257
human, direct gene therapy in, 150
immunotherapy for, 73
interventional genetics and, 115
*MDR*1-based gene therapy of, 135
Cancer therapy
gene transfer into hematopoietic cells and, 216
gene-modified TIL in, 188
Capsid proteins, viral, 43
Carcinoembryonic antigen (CEA) analysis, identification of sequences by, 141
Cationic liposomes, direct gene transfer and, 23
CD34+ cells
column immunoselection for, 218
Gaucher's disease and, 80, 319
human experiments using, 89
P-glycoprotein and, 128
CD34+ CD13+ blast cells, acute myeloid leukemia and, 207
CD34+ CD56+ blast cells, acute myeloid leukemia and, 207
CD4 cells, cytotoxic activity and, 175
CD4+ cells, antibody against, 148
CD8 cells, cytotoxic activity and, 175
CD8+ cells, antibody against, 148
Cell vesicle escape, mechanisms to accomplish, 40
Center for Biologies Evaluation and Research (CBER), 286
c-erb B2, *in vitro* experiments with, 124
Cervical carcinoma, adenovirus and, 97
Chemotherapy
ABMT and, 214
conventional, history of, 201
cytotoxic effects of, 222
mortality rate from, 215
resistance of melanoma to, 242
safety and, 104
target and, 256
Chimeric vectors, 65
Cholesterols, cationic, 26
Chronic myeloid leukemia (CML), 206
Cis-acting sequences, retroviral vectors containing, 60
Cis-platin-resistant cells, gene therapy of, 30, 34
Clathrin-coated pits
adenovirus and, 40
liposome preparations and, 35
Clinical protocols, design of, 289
Clinical trials, different types of, 284
Collaborative strategies, 301
Colorectal carcinoma (CRC), metastatic, VDEPT for, 107
Common cold, adenovirus and, 91
Conjunctivitis, adenovirus and, 91
CRIP cells, 75
CT26 cells
mγ-IFN vector-transduced, 173
parental nontransduced, 148
Cytolytic T lymphocyte (CTL)
allogeneic MHC gene and, 149
*MDR*1-based vectors and, 135
Cytolytic T lymphocyte (CTL) response
IL-12 facilitated, 73
mγ-IFN-expressing cells and, 174
Cyclosporine, P-glycoprotein and, 127
Cystic fibrosis (CF), gene therapy of, adenovirus vectors for, 92
Cystic Fibrosis Foundation, leadership of, in gene therapy, 17

Cytomegalovirus (CMV) infection, 300
Cytotoxic T-lymphocyte (CTL) response, 31

D17 cells, dog osteosarcoma, SNV and BLV replication and, 67
Damages, legally recognized, 296
3 β [N-(N′,N′,Dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol), 27
  direct gene delivery and, 145
  gene therapy *in vivo* with, 31
Dexamethasone, role of, with ribozymes, 256
DFG vector, 75
Differentiation, p53 and, 268
Dioleyl phosphatidylethanolamine (DOPE), 24
  direct gene delivery and, 145
N-[1-(2,3,-Dioleyloxy)propyl]-*N,N,N*-trimethylammonium chloride (DOTMA), 24
  direct gene delivery and, 145
  oligodeoxynucleotides and, 232
Direct gene delivery, methods of, 145
Direct gene transfer, cationic liposomes for, 23
Disease
  genetic vs. acquired, 13
  human, retroviruses and, 64
Disease targets for gene therapy, 3
DNA, heterologous, transport of, 47
DNA medicines, formulated, development of, 287
DNA viruses, retroviruses vs., 15
Double-stranded (DS) oligonucleotides, 321
Drug resistance genes, hematopoietic cells and, 222
Drug therapy, gene therapy vs., 2
Duty of care, 295

E1 proteins, 91
Encephalomyocarditis virus (EMCV), MFG vector and, 74
Endosome escape mechanism, lack of, 43
Endosomolysis facilitating gene delivery, adenoviral-mediated, 50
Endothelium
  gene transfer to, 260
  toxicity of antineoplastic agents to, 258
  tumor, 261
Environmental concern, FDA and, 292
Enzyme replacement, Gaucher's disease and, 307
Ethical issues, human genome project and, 22
Ex vivo approach, 14
Ex vivo gene marking, 206
Ex vivo gene therapy, FDA and, 286
Ex vivo gene therapy for arthritis, 83
Ex vivo genetically modified endothelial cells, 260
Experimental therapies, insurance companies and, 225

Fanconi's anemia, 223
Fc receptor γ chain, 192
Federal Drug Administration (FDA)
  clincical trials in gene therapy and, 21
  development of gene therapy and, 17, 18
  environmental concern of, 292
  evidence of efficacy in animal models required by, 202
  informed consent and, 297
  insertional mutogenesis and, 215
  list of Adverse Experiences maintained by, 290
  Phase I/II gene therapy clinical trial protocol approved by, 32
  recombinant biological products approved by, 12
  somatic cell therapy vs. gene therapy and, 14–15

Feasibility vs. efficacy of gene therapy, 285
FEM cells, human melanoma, 244
Fibroblast growth factor-1 (FGF-1), direct gene transfer and, 146
Fluorescence-activated cell sorter (FACS), NIH 3T3 cells and, 129
5-Fluorocytosine (5-FC, 5F-Cyt), 117
  cytosine deaminase gene and, 107
5-Fluorouracil (5-FU, 5F-Ura), 117
  cytosine deaminase gene and, 107
  hematopoietic cells and, 217
Follow-up, long-term, 290
Formacetal linkage, 235
fos-ribozyme, 255

G protein, packaging cells and, 282
G418-resistant colonies, 75
Gastrointestinal syndromes, adenovirus and, 91
Gaucher's disease
  CD34+ cells and, 319
  expensive therapy for, 226
  gene therapy for, 78
  glucocerebrosidase and, 307
Gene
  allogeneic class I MHC, direct gene transfer of, 147
  altered dihydrofolate reductase, 10
  bcl-2, antisense oligodeoxynucleotides against, 230–231
  bcr/abl, antisense oligodeoxynucleotides against, 230–231
  c-*erb*A, 266
  c-*erb*B-2, VDEPT and, 116
  c-*myb*, antisense oligodeoxynucleotides against, 230–231
  c-*myc*
  antisense oligodeoxynucleotides against, 230–231
  gene replacement or excision therapy and, 8
  c-*ras*, antisense oligodeoxynucleotides against, 230–231
  cloning of, 108
  chimeric, 119
  chimeric receptor, redirection of T cells using, 191
  cycstic fibrosis (CF), 90
  cystic fibrosis transmembrane conductase regulator (CFTR), 93
  cytosine deaminase (CD), cloning of, 108
  D612 heavy- and light-chain, LS-174T cells transduced with, 155
  E. coli lacZ, 92
  env
    MFG vector and, 74
    retroviruses encoding, 60
  α-fetoprotein (AFP), VDEPT and, 116
  GADD45, 266
  gag, 309
    retroviruses encoding, 60
  β-galactosidase receptor, 42
  H-2K^b, 324
  H-2K^s, direct gene transfer and, 148
  H-2^s, mouse MHC class I, 31
  hamster *pgp*, 127
  HLA B7
    DC-Chol cationic liposomes and, 32
    endogenous vascular cells and, 147
    metastatic melanoma and, 150
  human adenosine deaminase (ADA), 321
  human multidrug resistance (*MDR*1), 126
  lacZ
    organs stained for, 101
    endothelial cells and, 260
  mAb, carcinoma cells transduced with, 160
  multidrug resistance (*mdr*, MDR, MDR-1), 10, 127
    p53 and, 269
  muscle creatin kinase (MCK), 266
  myc, gene replacement or excision therapy and, 7
  neomycin phosphotransferase (*neo*), 327

neo^R, acute myeloid leukemia and, 207
p53
expressed in all tissues, 265
gene replacement or excision therapy and, 7–8
pCD_2, 119
pol, retroviruses encoding, 60
ras, gene replacement or excision therapy and, 7
rex, 65
Sh ble, 259
tax, 65
thymidine kinase (TK), VDEPT and, 106–107
TNF, 334
transduced TIL and, 190
WAFI/Cip-I, 266
Gene addition therapy, 8
Gene constructs, retrovirus-mediated gene transfer and, 119
Gene marking, feasibility of, 206
Gene marking trial, 284
Gene replacement or excision therapy, 7
Gene therapy
definition of, 2, 12
disease targets for, 3
impact of, on medicine and society, 12
risks of, 20
wasting time with, 201
Gene therapy protocols (*ex vivo*), 14
Gene therapy protocols (*in vivo*), 16
Gene transfer
hematopoietic cells and, 216
high-efficiency, 36
mortality rate acceptable in, 214
recombinant virion-mediated, 47
Gene transfer efficiency, VDEPT and, 112
Genetic lesions, neoplastic transformations and, 6
Genetic variability, safety of, 63
Genetics, interventional, and cancer, 115
GINa.40 retroviral vector, 218
Gl/S border, 267
Glucocerebrosidase (GC)
expression of, 78
murine myoblasts and, 307
Gly185Val mutant, 132
GP+E86 cells, supernatants of, 129
Granulocyte colony-stimulating factor (G-CSF), Gaucher's disease and, 227
Granulocyte-macrophage colony-stimulating factor (GM-CSF), 73
redirected TIL specifically secreting, 193
Granulocyte-monocyte colony-stimulating factor (GM-CSF), 217

H-*ras* ribozyme, 243
Health and Human Services (HHS), informed consent and, 297
Heart, adenovirus and, 94
HeLa cells, adenovirus and, 41, 97
Helper cells, replication proteins and, 61
Hematopoietic cells, gene transfer into, 216
Hematopoietic stem cells, 327
Hepatic cells, 331
Hepatitis B, genetically redirecting T cells with chimeric receptors and, 193
Hepatocellular carcinoma (HCC), VDEPT and, 116
Herpes simplex virus type I (HSV-1), 275
Hexon protein, adenoviral, 45
HIV/gene therapy, Viagene, 301
HLA loss in tumors, 202
Human antimouse antibody (HAMA), 192
Human β-interferon retroviral provector (pHuγ-IFN), construction of, 168
Human Gene Therapy Subcommittee of RAC, 289
abolishment of, 17, 19

Human immunodeficiency virus (HIV), genetically redirecting T cells with chimeric receptors and, 193
Human immunodeficiency virus long terminal repeat promoter (HIV-LTR), 26
Human immunodeficiency virus type 1 (HIV-1), AIDS and, 64
Human immunodeficiency virus-1-*trans*-activator (HIV-1-tat) protein, 29
Human subjects
  gene therapy protocols (*ex vivo*) initiated in, 14
  gene therapy protocols (*in vivo*) initiated in, 14
Human T cell leukemia virus type I (HTLV-1), adult T cell leukemia and, 64
Hygromycin resistance (Hyg^R), 66

Immunoglobulin G (IgG), LS-174T cells and, 156
Immunomodulation, tumors more amenable to, 200
In vitro, expression of c-erb B2, 124
In vitro vs. *in vivo*, adenovirus system and, 57
In vivo, site-specific gene transfer into vascular cells, 146
In vivo approach, 15
In vivo gene transfer, adenovirus-mediated, 90
In vivo inhibition of carcinoma cells, 160
In vivo selectable markers, power and promise of, 136
In vivo selection of cells, 222
Indium-111, 188
Industrial sector, funding from, 285
Industry norms, 297
Influenza-like illness, adenovirus and, 91
Informed consent, 289, 297
Insertional mutagenesis, 215
Institional Biosafety Committees (IBCs), 289
Institutional Review Boards (IRBs)
  progress in gene therapy slowed by, 17
  technical expertise of, 289
Insurance companies, experimental therapies and, 225
Interleukin-1 receptor antagonist protein (IL-lra, IRAP), 75
  bone marrow transplant experiments with, 89
  systemic expression of, 85
Interleukin-2 (IL-2)
  cancer therapy and, 188
  durable complete remission information and, 198
Interleukin-3 (IL-3), differentiation vs. renewal and, 234
Interleukin-12 (IL-12)
  antitumor effect of, 88
  gene therapy for cancer and, 73
Internal ribosome entry sequence (IRES), 66
  *MDR*1-based vectors and, 135
  MFG vector and, 74
Invasive surgical procedures, therapies involving, 286
Inverse terminal repeat (ITR), adenovirus vector and, 91
Investigational drug (IND) process, 285

K562 cells, 336
Knockout mice, transgenic, p53 and, 267

L33 cells, mγ-IFN vector-transduced, 172
Lectins, 56
Legislative solutions, lobbying for, 302
Leukemic inhibiting factor (LIF), 217
Liability, 20, 294, 305, 306

Lipofectin
composition of, 24
direct gene delivery and, 145
Liver, adenovirus and, 94
LNL6 retroviral vector, 218
Long terminal repeats (LTRs), 190, 327
cis-acting sequences and, 60
MFG-glucocerebrosidase and, 314
LS-174T cell, D612 mAb light- and heavy-chain genes introduced into, 155
Lung, delivery to, 93
Lung lavage, 102
Lymphokine-activated killer (LAK) cells, cancer immunotherapy and, 188
Lymphokine-activated killer (LAK) splenocytes, 334
Lysis, resistance to, 180

M7609 cells, 336
Magnesium chloride, ribozymes and, 255
Major histocompatibility complex (MHC) class I gene, 31
Major histocompatibility complex (MHC) class I protein, effect of mγ-IFN expression on, 172
MCF 7 breast cancer cells, p53 and, 274
MDA-MB468 breast cancer cells, p53 and, 274
MDM-2, 267
Medicine, impact of gene therapy on, 12
Melanocytes, TPA and, 248
Melanoma, cutaneous, incidence of, 242
Melanoma cells, hγ-IFN-transduced, 177
Methylcholanthren-induced mouse fibrosarcoma (Meth-A) cells, 334
MFG vector, 74
selectable marker in, 89
MFG-glucocerebrosidase, 308
MFG-lacZ infection, 313
Minimal residual disease (MRD), 206
Molecular conjugate vectors, adenovirus-polylysine complexes and, 51
Molecular pathobiology, birth of, 1
Monoclonal antibodies (mAb)
potential therapeutic applications of, 154
tumor-associated antigens and, 199
Monoclonal antibody (mAb) 43A, 261
Monoclonal antibody (mAb) 8E4-L, 312
Multidrug transport, biology of, 127
Murine embryonic stem cell virus (MESV), 327
Murine γ-interferon retroviral provector (pMuγ-IFN), construction of, 168
Murine myoblasts, transduction of human glucocerebrosidase by, 307
Muscle, skeletal, adenovirus and, 94
Myogenic organoid, Gaucher's disease and, 318

National Institutes of Health (NIH)
advocate for gene therapy at, 22
development of gene therapy and, 16
informed consent and, 225
Phase I/II gene therapy clinical trial protocol approved by, 32
Points to Consider from, 286
Natural killer (NK) cells, antibody-independent cytotoxicity mediated by, 157
Natural killer cell stimulatory factor (NKCSF), IL-12 termed, 73
Negligence, 294
Neo-expression plasmid, 75
Neo-expression vector, 89
Neomycin phosphotransferase (Neo^R), marker gene encoding, 189
Neoplastic disease, initial efforts of gene therapy directed at, 3

Neuroblastoma, source of relapse in, 210
NIH 3T3 cells
  ability to transduce, 129
  Sh ble in, 259
  targeting, 309
Nonviral gene transfer methods, limitations of, 38
Nude mice
  administration of D612 mAb to, 160
  athymic, mγ-IFN-expressing cells in, 173
  in vivo experiments in, 165

Oligodeoxynucleotides (ODNS)
  antisense, gene inhibition by, 228
  methylphosphonate, 232
  phosphodiester, 233
Ornithine transcarbamylase (OTC) protein synthesis, 94

P-glycoprotein
  interaction between drug and, 142
  normal and malignant tissues containing, 254
  multidrug transport and, 127
p53
  mutant, 269
  P-glycoprotein and, 142
  wild-type, 265
p53 tumor suppressor, 265
  cancer gene therapy with, 270
PA-12 cells, supernatants of, 129
PA317 cells, irradiated, 155
PA317 MLV helper cell line, 61
Packaging
  provirus RNA, 68
  recombinant amphotropic viruses within human body and, 141
Packaging cell lines (PCL), retroviral, generation of, 169
Packaging cells, replication proteins and, 61
Pancreas carcinoma, VDEPT against, 118
PE13 cells, p53 expression in, 281
Pharmaceutical companies, development of gene therapy and, 17
Pharyngitis, acute, adenovirus and, 91
Phenotype, 288
Phenotypes, gene addition therapy and, 9
Phosphorothioate oligonucleotides, 321
Phosphorylation differences, stabilization and, 254
pJD214*hyg* vector, 67
pKB408IH vector, 66
pKB421 vector, 66
Platelet-derived growth factor (PDGF) B chain, direct gene transfer and, 146
Pneumonia, adenovirus and, 91
Points to Consider, 286
Polymerase chain reaction (PCR), delivered DNA and, 31
Preclinical issues, 285
Prodrug, nontoxic, gene addition therapy and, 10
Program design, 299
Proliferating cell nuclear antigen (PCNA), 269
Protein kinase C (PKC)
  cationic liposomes and, 26
  oligodeoxynucleotides and, 230
Provirus integration, safety of, 63
pSV2CAT DNA, 331
pSV2neo, 75, 78
pTH-CD500 vector construct, 119
Public, ability of, to understand concepts, 305
Public attention and scrutiny, clinical trials and, 284
Public review, RAC process includes, 300
Pulmonary emphysema, adenovirus and, 95
Pulmonary fibrosis, treatment strategies of, 258

Purine nucleotide phosphorlase (PNP), early gene therapy applications and, 3

Qualitative differences in cells, quantitative differences vs., 104

Ras-ribozyme, 255
Rat
  BLV antibodies and, 69
  cotton, 93, 103
Rat embryo fibroblasts (REF), p53 and, 274
Receptor-mediated gene delivery, strategies to accomplish, 38
Recombinant DNA, new diagnostic techniques based on, 12
Recombinant DNA Advisory Committee (RAC)
  composition of, 289
  evidence of efficacy in animal models required by, 202
  Gaucher's disease and, 80
  gene therapy issues and, 17, 19
  informed consent and, 225
  insertional mutogenesis and, 215
  Points to Consider from, 286
  public review and, 300
Recombinant viral vectors, adenovirus-polylysine complexes and, 51
Recombinant virion-mediated gene transfer, 47
Regulatory requirements, 297
Relapse, 207
Replication cycle of a retrovirus, 59-60
Residual disease, 226
Restriction fragment length polymorphism (RFLP), 207
Retroviral vectors
  adenovirus vectors and, 275
  cis-acting sequences and, 60
Retrovirus, replication cycle of, 59–60
Retroviruses, DNA viruses vs., 15
Rex response element (RXRE), 69
Ribozymes, antisense molecules vs., 254
Risk
  ABMT and, 214
  downplay of, 299
  retrovirus-mediated gene therapy and, 63
Risk vs. benefit
  clinical trials and, 284
  gene therapy protocols and, 292
Risks of gene therapy, 20

Safety
  ABMT and, 211, 215
  absolute, 293
  AdCFTR and, 93
  adenovirus vectors and, 97
  chemotherapy and, 104
  genetic variability and, 63
  hematopoietic cells and, 218
  provirus integration and, 63
  recombinant virion gene transfer and, 36
Salivary glands, adenovirus and, 94
Saos-2 cells, p53 and, 274
Severe combined immunodeficiency (SCID), 223
Sickle cell anemia, molecular etiology of, 1
Simian virus 40 (SV40), cationic liposomes and, 26
  p53 and, 270
  polyadenylation signal of, 91
Site-specific sequence replacement or correction, 7
SNV helper cell line, 61
Society, impact of gene therapy on, 12
Somatic cells, gene therapy and, 12
Somatic gene therapy, designing clinical trials of, 283
Species specificity, 288
Specificity of killing, specificity of homing vs., 198
Stabilization, phosphorylation differences and, 254
Standard of care, meeting, 296

Stem cell factor (SCF), 217
  use of, to mobilize peripheral blood cells, 227
Stiver v. Parker et al., 299
Strategies, gene therapy, for treating neoplastic disease, 6
Streptoalloteichus hindustanus (Sh ble), 259

T-cell receptor (TcR), immunotherapy and, 154
T-cell receptor (TcR) C_β and ζ chains, 192
T7 RNA polymerase, delivery of, 27
T98G glioblastoma cells, p53 and, 274
Target, chemotherapy and, 256
Targeting, endothelial cell, 257
TATA-binding factor (TBP), 266
Taxol, neurological toxicity and, 139
Technologies, gene transfer, 11
Testing, preclinical, 286
12-0-Tetradecanoylphorbol-13-acetate (TPA), melanocytes and, 248
Thalidomide cases, 306
Therapeutic intent, trials with, 284
Thioformacetal linkage, 235
3T3 cells, 75
Tumor infiltrating lymphocytes (TIL cells), 73
  gene addition therapy and, 10
  gene-modified, 188
  genetic manipulation of, 3
  indium-111–labeled, 188
  *MDR*1-based vectors and, 135
  Neo_R-transduced, 189
  untransduced, 197
Titer, toxicity and, 141
Toxicity, liver, 138
Toxicity analysis, preclinical, direct gene transfer and, 149
Transcriptional regulatory sequence (TRS), VDEPT and, 107
Transferrin receptor (Tf-R), 336
Transferrin-polylysine conjugates, adenovirus vs., 41
Transgene expression, regulation of, 27
Tritiated cytosine (cytosine 5-[^{3}H]), 121
TS/A cells, 76
Tumor cells
  adenovirus-mediated gene transfer to, 96
  effects of p53 expression on, 271
Tumor necrosis factor (TNF)
  dose of, in mouse and man, 201
  toxicity of, 197
Tumor necrosis factor-α (TNF-α), 73
Tumor necrosis factor-α (TNF-α) cDNA, transduction of TIL with, 189
Tumor-specific prodrug activation therapy (TSPAT), 123
Tumorigenicity
  decreased, Mγ-IFN and, 180
  p53 and, 268

VACO 235 cells, p53 and, 274
Vascular diseases, adenovirus and, 95
Venblastin, taxol and, 139
Verapamil, P-glycoprotein and, 127
Vesicular stomatitis virus (VSV), p53 and, 275
Viagene, 301, 306
Viral vectors, problems associated with, 37
Virus-directed enzyme/prodrug therapy (VDEPT)
  cancer and, 116
  description of, 105

WiDr cells, cytosine deaminase and, 108

Yeast tRNA, coating vector with, 56

Index of Contributors

(Page numbers in italics refer to comments made in discussion.)

Abdel-Wahab, Z., 167–187
Aksentijevich, I. 126–138
Anderson, W. F., 204–214
Aramaki, Y., 331–333
Aronow, B. J., 321–323
Austin, E. A., 104–114

Bahnson, A., 72–88, 307–319
Bansal, V., 307–319
Barber, J. R., 167–187
Barranger, J. A., 72–88, 307–319, *319–320*
Barsoum, J. 23–34
Bodine, D. M., 216–224
Boggs, S. S., 72–88
Boris-Lawrie, K., 59–70, *71, 101*
Bottega, R., 23–34
Brenner, M. K., 204–214, *214–215, 224, 225–227*
Brody, S. L., 90–101, *101–102, 103, 198*
Brookens, M. A., 257–264
Burrascano, M., 167–187

Calmels, T. P., 257–264
Cardarelli, C. O., 126–138
Carter, C., 216–224
Cassell, A., 216–224
Chang, A., 144–153
Chong, K., 167–187
Cottler-Fox, M., 216–224
Cowan, K., 216–224
Crystal, R. G., 90–101
Curiel, D. T., 36–56, *56, 57, 58, 88–89, 102*

Darrow, T., 167–187
Donahue, R., 216–224
Doren, S., 216–224
Dunbar, C. E., 216–224, *224, 226, 227*

Epand, R. M., 23–34
Ess, K. C., 321–323
Evans, R. R., 257–264
Evans, C. H., 72–88

Farhood, H., 23–34
Finch, M. D., 154–165
Florenes, V. A., 242–253
Fodstad, O., 242–253
Fox, B., 144–153
Friedmann, T., 265–280
Froehler, B. C., 228–241
Fujii, S., 334–335
Funato, T., 242–253

Galea-Lauri, J., 72–88
Gangavalli, R., 167–187
Gao, X., 23–34
Geliebter, J., 324–326
Germann, U. A., 126–138
Gordon, D., 144–153
Gottesman, M. M., 126–138, *139, 141, 142*

Hara, T., 331–333
Harris, J. 115–124
Hawley, R. G., *89*, 327–330
Heslop, H. E., 204–214
Horng, M., 242–253
Howard, B., 167–187
Huang, L., 23–34, *34, 35, 198, 255, 281*

Huber, B. E., 1–5, 6–11, 20, 56, 71, 104–114, *124, 125, 139, 140, 141, 197, 200, 214, 215, 280, 281, 292*
Hung, G., 72–88
Hurst, H., 115–124
Hutton, J. J., 321–323
Hwu, P., 188–197, *197, 198, 199, 201, 202*

Ihle, J. N., 204–214
Itoh, Y., 334–335, 336–337

Jaffee, M., 144–153
Jiao, L., 242–253
Johnson, C. S., 257–264
Jolly, D. J., *142*, 167–187, *187, 200, 201, 203*
Jones, R. J., 228–241

Kashani-Sabet, M., 242–253
Kashfian, B. I., 242–253
Kashmiri, S. V. S., 154–165
Kelley, W. N., 12–18, *19, 20, 21, 22*
Kesari, K. V., 324–326
Kohgo, Y., 334–335, 336–337
Koike, K., 331–333
Koshita, Y., 334–335, 336–337
Krance, R. A., 204–214

Lauterbach, K., 242–253
Lazo, J. S., *18–19, 20, 21*, 23–34, *142, 201–202, 226, 253–254*, 257–264, *306, 319*
Ledley, F. D., *20–21, 57, 102, 200–201*, 283–292, *292–293, 305*
Lemoine, N. 115–124
Li, J., 307–319
Lotze, M. T., 72–88
Lucht, L., 307–319

McCallister, T., 167–187
McDonagh, K., 216–224
Masci, A. M., 154–165
Matsuyama, T., 336–337
Matteucci, M. D., 228–241
Milligan, J. F., 228–241
Mirro, J., Jr., 204–214
Modzelewski, R. A., 257–264
Moen, R. C., 204–214
Mowery-Rushton, P., 307–319
Mueller, G., 72–88

Nabel, E. G., 144–153
Nabel, G. J., *34, 35*, 144–153, *198–199, 200, 201, 202, 203*
Neda, H., 334–335, 336–337
Nienhuis, A. W., 216–224
Niitsu, Y., 334–335, 336–337

O'Shaughnessy, J., 216–224
Ohashi, T., 72–88
Ohta, Y., 242–253

Palmer, J. G., 294–305, *305, 306*
Pastan, I., 126–138
Patrene, K., 72–88
Pitt, B. R., 257–264
Plautz, G. E., 144–153
Primus, F. J., 154–165, *165–166*

Richards, C. A., 104–114
Rill, D. R., 204–214
Robbins, P. D., 72–88, *89*
Roemer, K., 265–280, *280–282*
Rosenberg, S. A., 188–197

Scanlon, K. J., *35*, 242–253, *254–255, 256*
Schlom, J., 154–165
Severinsson, L., 167–187
Shitara, T., 242–253

Siegler, H. F., 167–187
Sikora, K., 115–124, *124–125, 142–143*
Son, K., 23–34
Sorrentino, B., 216–224
Sugimoto, Y., 126–138

Tahara, H., 72–88
Takada, S., 331–333
Takahashi, M., 334–335, 336–337
Temin, H. M., 59–70
Tone, T., 242–253
Tsai, P., 242–253
Tsuchiya, S., 331–333

Vervaert, C., 167–187

Watanabe, N., 334–335, 336–337
Watkins, S. C., 307–319
Wetzel, S. A., 154–165

Yang, Y-Y., 23–34
Yang, Z-Y., 144–153
Yoshida, E., 242–253

Zitvogel, L., 72–88